Sellas presses ahead with fast track designation for lymphoma
The US Food and Drug Administration (FDA) has granted a fast track designation to Sellas Life Sciences Group’s SLS009 for…
cancer treatment
-
-
XNK partners with Swedish hospital to develop AML therapy
XNK Therapeutics has partnered with Sweden-based research university Karolinska University Hospital to evaluate the former’s natural killer (NK) cell therapy…
-
PROTACs show promise for cancer treatment
Development of PROTACs (PROteolysis TArgeting Chimeras) has advanced fairly rapidly as excitement grows over their potential to selectively degrade proteins…
